Navigation Links
CASiGEN Pharma Receives A World-wide Exclusive License From GIBH To Bring New Potential Diabetes Treatments To The Global Market
Date:5/17/2012

example of how universities and research institutions in mainland China could take advantage of Hong Kong's international business outlook and get high level support at HKSTPC to take the company efficiently through its early development stage."

Commenting about the license agreement and potential future home of CASiGEN at HKSTP, Mr. Mikael Oerum, Chairman of CASiGEN Pharma and Founding Partner of Ventac Partners, said: "CASiGEN Pharma is committed to the development of novel drugs for the treatment of metabolic diseases, in particular diabetes type 2. CASiGEN combines international pharmaceutical business expertise with novel therapeutic discoveries originating from GIBH to enable fast and efficient drug development. The diabetes program at CASiGEN focuses on the identification and development of orally available, small molecules acting on a recently validated drug target, ERR-alpha, in type 2 diabetes. Our goal is to improve  the effect of insulin action by making the body more sensitive to insulin. We believe by locating the company in HKSTP CASiGEN will be situated optimally in the region. HKSTP  is an excellent supporter of young biotech companies with a global outlook. It is furthermore anticipated that CASiGEN will form a partnership with a mainland company to serve the China market for new anti-diabetic drugs."

GIBH is a government-sponsored scientific research institute affiliated with the Chinese Academy of Sciences. With more than 300 staff members and 200 graduate students, the institute engages in three major areas of research, stem cell biology, chemical and synthetic biology and infection/immunity. GIBH's mission is to serve citizens of China and the world through commitment and discovery by integrating both biological and chemical sciences for the improvement of human health. For more information, see www.gibh.cas.cn.

Hong Kong Science and Technology Parks Corporation '/>"/>

SOURCE Ventac Partners
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015 Redwood Pharma AB ... Co., Ltd., operating in both the US and ... IntelliGel ® supramolecular hydrogel technology in its lead ... ophthalmic therapies. The Broda technology offers many unique competitive ... free-forming liquid and with low concentrations of polymer the ...
(Date:7/2/2015)... TX and VANCOUVER , July ... "Company") (TSX-V: EPI) announced today that its common shares have ... Market ("NASDAQ") under the symbol "EPIX". ESSA will ... will retain its listing on the TSX Venture Exchange under ... listing of the common shares on the NASDAQ, each of ...
(Date:7/2/2015)... , July 2, 2015  Before you head outdoors ... so you can stay safe and healthy. Take steps to ... Infographic http://nyackhospital.org/summersafety Protect Your Skin From ... the sun can increase your risk of skin cancer. To ... as much as possible, especially during midday hours. Wear a ...
Breaking Medicine Technology:Redwood Pharma Licenses Novel Hydrogel Drug Delivery Technology From Broda Technologies 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3
... July 30 Zargis Medical Corp., a majority-owned subsidiary of ... Care System (VAPAHCS), a northern California based hospital group that ... hospitals, recently purchased 15 Zargis Cardioscan systems. , ... The VA Palo Alto Health Care System (VAPAHCS) consists ...
... 29 Sequenom, Inc. (Nasdaq: SQNM ), will report second quarter 2010 financial results after market close ... 1:30 pm Pacific Time ( 4:30 pm Eastern Time ) on the same day. , ... Information: , , , ... International callers: +1- 857-350-1603 , , ...
Cached Medicine Technology:Veterans Administration Health Care System Purchases 15 Zargis Cardioscan Systems 2Veterans Administration Health Care System Purchases 15 Zargis Cardioscan Systems 3Sequenom Announces Date of Second Quarter 2010 Financial Results and Conference Call 2
(Date:7/3/2015)... ... 2015 , ... B. E. Smith, the only full-service leadership ... national chief nursing officer recruitment for Jane Phillips Medical Center in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... Medical Director of its Frisco facility. , “We are pleased to announce that Dr. ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Manzanares ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... sweetFrog Enterprises, ... Mississippi. The opening is the first sweetFrog store located in Mississippi. The premium frozen ... companies in 2014. , The store, located at 104 Railroad Avenue, New Albany, MS ...
(Date:7/2/2015)... ... July 02, 2015 , ... When Walker Parking Consultants ... University of Minnesota, they knew it would save the university energy and maintenance ... choice: the total energy savings after installation was an impressive 89 percent, which ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... As Americans ... like the hot temps, skin cancer is on the rise. July is UV Safety ... are raising awareness about the importance of getting skin checks. Experts say most skin ...
Breaking Medicine News(10 mins):Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4
... numbers are staggering --,over 20% of people living in ... the impairment or disability which creates dependency and,poverty in ... and political opportunities," says Ron Nabors, Chief,Executive Officer of ... stand up and speak out on the,International Day for ...
... Oct. 16 Children in the South Bay,suffering ... conditions can,now receive specialty care from Lucile Packard ... hospital,s new South Bay,Specialty Center in Los Gatos ... all the hallmarks of its parent institution. ...
... WEST CHESTER, Ohio, Oct. 16 AtriCure, Inc.,(Nasdaq: ... leader in cardiac surgical,ablation products, today announced that ... which physicians have adopted to,treat atrial fibrillation (AF), ... Dr. James H. McClelland, an,electrophysiologist, and colleagues from ...
... the U.S. Food and Drug,Administration,s (FDA,s) Cardiovascular ... majority of members voted to recommend the ... FOSRENOL(R),(lanthanum carbonate), to treat hyperphosphatemia (elevated levels ... disease (CKD) Stage 4 patients.,Currently, FOSRENOL is ...
... and Advertising ... Distribution Agreements, WebMD Announces Third Quarter Earnings ... WebMD Health Corp. (Nasdaq:,WBMD), the leading provider of health information services, ... Preliminary Results for the Three Months Ended September 30, 2007 ...
... Oct. 16 HLTH Corporation,(Nasdaq: HLTH ) today ... months ended September 30, 2007 at approximately 4:00 pm ... previously announced, HLTH Corporation,s 84% owned,subsidiary, WebMD Health Corp. ... their financial results for the three months ended September ...
Cached Medicine News:Health News:CBM USA stands up and speaks out to world leaders on the International Day for the Eradication of Poverty 2Health News:Packard Children's Hospital Opens New South Bay Specialty Clinic Bringing Specialty Care Close to Home 2Health News:Published Results Using AtriCure Minimally Invasive Products 2Health News:Published Results Using AtriCure Minimally Invasive Products 3Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 2Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 3Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 4Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 5Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 6Health News:FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia 7Health News:WebMD Reports Preliminary Third Quarter Financial Results 2Health News:WebMD Reports Preliminary Third Quarter Financial Results 3Health News:WebMD Reports Preliminary Third Quarter Financial Results 4Health News:WebMD Reports Preliminary Third Quarter Financial Results 5Health News:WebMD Reports Preliminary Third Quarter Financial Results 6Health News:WebMD Reports Preliminary Third Quarter Financial Results 7Health News:WebMD Reports Preliminary Third Quarter Financial Results 8Health News:WebMD Reports Preliminary Third Quarter Financial Results 9Health News:WebMD Reports Preliminary Third Quarter Financial Results 10Health News:WebMD Reports Preliminary Third Quarter Financial Results 11Health News:HLTH Corporation Announces Third Quarter Earnings Release Date and Conference Call 2
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Pefakit in-TDT Calibrators and Controls...
PT-HS with Calcium - 2 ml...
Medicine Products: